MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/coc.0000000000001300

Медицинская библиотека · American journal of clinical oncology · 2026

Hepatotoxicity of External Radiotherapy for Hepatocellular Carcinoma in the Setting of Prior Yttrium-90 Radioembolization.

Feldkamp Sarah, Niewiara Claire, Nelson Bailey, Wang Kyle, Nahab Bashar, Lee Darren, Semaska Nedas, Assi Ismael, Kharofa Jordan

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVES

To evaluate the hepatotoxicity and clinical outcomes following external beam radiation therapy (EBRT) in patients with hepatocellular carcinoma (HCC) previously treated with Yttrium-90 radioembolization (Y-90), a setting in which cumulative liver radiation exposure raises concern for increased toxicity risk.

METHODS

We performed a retrospective review of 94 HCC patients treated with EBRT from 2016 to 2024, including 15 treated with Y-90. Hepatotoxicity was assessed using Albumin-Bilirubin (ALBI) score changes at 3 and 6 months post-EBRT. Secondary outcomes included CTCAE toxicity, local control, and survival. Treatment details, prior locoregional therapies, and dosimetric parameters were collected. Fisher exact tests and Kaplan-Meier analyses were used for statistical comparisons.

RESULTS

Baseline demographics and liver function were similar between groups. Over half the Y-90 cohort (53%) received fractionated proton therapy. At 6 months, grade 1 and 2 ALBI deterioration occurred in 2 (13%) and 4 patients (27%) with prior Y-90, compared with 17 (22%) and 21 patients (27%) without prior Y-90 ( P =0.77). Grade ≥2 CTCAE toxicity occurred in 2 patients (13%) with prior Y-90 and in 5 patients (6%) without. Local control was 92% with no local failures in patients treated after Y-90. Median OS was 39 months without prior Y-90 and 34 months with prior Y-90 ( P =0.89).

CONCLUSIONS

EBRT following Y-90 was not associated with increased hepatotoxicity or inferior oncologic outcomes compared with EBRT alone. When delivered with individualized planning, including fractionation, EBRT represents a safe and effective salvage modality for patients with residual or recurrent HCC after Y-90.

Для цитирования: Feldkamp Sarah, Niewiara Claire, Nelson Bailey, Wang Kyle, Nahab Bashar, Lee Darren, Semaska Nedas, Assi Ismael, Kharofa Jordan. Hepatotoxicity of External Radiotherapy for Hepatocellular Carcinoma in the Setting of Prior Yttrium-90 Radioembolization.. American journal of clinical oncology. 2026. DOI: 10.1097/coc.0000000000001300.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.